Overview

  • Product name

  • Description

    Guinea pig polyclonal to C Peptide
  • Host species

    Guinea pig
  • Specificity

    Ab30477 recognises C peptide: 100%; Pro insulin: < 4.0%, Insulin: 0.0%, Glucagon: 0.0%, Pancreatic Polypeptide: 0.0%.
  • Tested applications

    Suitable for: ELISA, RIA, ICC/IFmore details
  • Species reactivity

    Reacts with: Human
  • Immunogen

    Full length C Peptide protein (Human).

  • General notes


    C Peptide is part of the molecule of Proinsulin, that consists of three parts: C Peptide and two long strands of amino acids (called the alpha and beta chains) that later become linked together to form the insulin molecule. From every molecule of proinsulin, one molecule of insulin plus one molecule of C Peptide are produced. C peptide is released into the blood stream in equal amounts to insulin. A test of C peptide levels will show how much insulin the body is making. Insulin decreases blood glucose concentration. It increases cell permeability to monosaccharides, amino acids and fatty acids. It accelerates glycolysis, the pentose phosphate cycle, and glycogen synthesis in liver.

Properties

  • Form

    Liquid
  • Storage instructions

    Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C or -80°C. Avoid freeze / thaw cycle.
  • Storage buffer

    Preservative: None
    Constituents: PBS, pH 7.6.
  • Purity

    Whole antiserum
  • Primary antibody notes

    C Peptide is part of the molecule of Proinsulin, that consists of three parts: C Peptide and two long strands of amino acids (called the alpha and beta chains) that later become linked together to form the insulin molecule. From every molecule of proinsulin, one molecule of insulin plus one molecule of C Peptide are produced. C peptide is released into the blood stream in equal amounts to insulin. A test of C peptide levels will show how much insulin the body is making. Insulin decreases blood glucose concentration. It increases cell permeability to monosaccharides, amino acids and fatty acids. It accelerates glycolysis, the pentose phosphate cycle, and glycogen synthesis in liver.
  • Clonality

    Polyclonal
  • Isotype

    IgG
  • Research areas

Applications

Our Abpromise guarantee covers the use of ab30477 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
ELISA Use at an assay dependent concentration.
RIA Use at an assay dependent concentration.
ICC/IF Use at an assay dependent concentration. PubMed: 25365581

Target

  • Function

    Insulin decreases blood glucose concentration. It increases cell permeability to monosaccharides, amino acids and fatty acids. It accelerates glycolysis, the pentose phosphate cycle, and glycogen synthesis in liver.
  • Involvement in disease

    Defects in INS are the cause of familial hyperproinsulinemia (FHPRI) [MIM:176730].
    Defects in INS are a cause of diabetes mellitus insulin-dependent type 2 (IDDM2) [MIM:125852]. IDDM2 is a multifactorial disorder of glucose homeostasis that is characterized by susceptibility to ketoacidosis in the absence of insulin therapy. Clinical fetaures are polydipsia, polyphagia and polyuria which result from hyperglycemia-induced osmotic diuresis and secondary thirst. These derangements result in long-term complications that affect the eyes, kidneys, nerves, and blood vessels.
    Defects in INS are a cause of diabetes mellitus permanent neonatal (PNDM) [MIM:606176]. PNDM is a rare form of diabetes distinct from childhood-onset autoimmune diabetes mellitus type 1. It is characterized by insulin-requiring hyperglycemia that is diagnosed within the first months of life. Permanent neonatal diabetes requires lifelong therapy.
    Defects in INS are a cause of maturity-onset diabetes of the young type 10 (MODY10) [MIM:613370]. MODY10 is a form of diabetes that is characterized by an autosomal dominant mode of inheritance, onset in childhood or early adulthood (usually before 25 years of age), a primary defect in insulin secretion and frequent insulin-independence at the beginning of the disease.
  • Sequence similarities

    Belongs to the insulin family.
  • Cellular localization

    Secreted.
  • Information by UniProt
  • Database links

  • Alternative names

    • IDDM 2 antibody
    • IDDM2 antibody
    • ILPR antibody
    • ins antibody
    • INS_HUMAN antibody
    • Insulin A chain antibody
    • IRDN antibody
    • MODY10 antibody
    • Proinsulin antibody
    see all

References

This product has been referenced in:

  • Wang X  et al. Point mutations in the PDX1 transactivation domain impair human ß-cell development and function. Mol Metab 24:80-97 (2019). Read more (PubMed: 30930126) »
  • Pettinato G  et al. ROCK inhibitor is not required for embryoid body formation from singularized human embryonic stem cells. PLoS One 9:e100742 (2014). ICC/IF ; Human . Read more (PubMed: 25365581) »
See all 3 Publications for this product

Customer reviews and Q&As

1-2 of 2 Abreviews or Q&A

Application
Immunocytochemistry/ Immunofluorescence
Sample
Rat Cell (Rat INS1 Cell line)
Permeabilization
Yes - 0.5% Triton X -100
Specification
Rat INS1 Cell line
Blocking step
5% Goat serum and 1% BSA as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 5% · Temperature: 22°C
Fixative
Paraformaldehyde

Abcam user community

Verified customer

Submitted Feb 28 2019

Question
Answer

Thank you for your enquiry.

I have spoken to our supplying lab and found that the concentration of ab30477 is not determined. The antibody is sold based on sensitivity in radioimmunoassay (RIA) QC testing, so each lot may have a higher or lower concentration.

I'm sorry I could not be of further assistance in this instance. Please contact us again if you have any further questions.

Read More

Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"
For licensing inquiries, please contact partnerships@abcam.com

Sign up